查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1446477

抗凝血劑市場規模、佔有率、趨勢分析報告：按藥物分類、給藥途徑、應用、地區和細分市場預測，2024-2030年

Anticoagulants Market Size, Share & Trends Analysis Report By Route of Administration, By Drug Category, By Application, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10個工作天內

價格

抗凝血劑市場成長與趨勢：

Grand View Research, Inc.的最新報告顯示，到2030年，全球抗凝血藥物市場預計將達到604億美元，在2024-2030年預測期內複合年成長率為8.7%。

這個市場主要是由心血管疾病（CVD）盛行率的增加和人口老化所推動的。根據世界衛生組織統計，2019年，CVD造成了全球大部分死亡，死亡人數達1,790萬人，佔全球死亡人數的32%。其中 85% 的死亡是由於心臟病和中風造成的。此外，在因非傳染性疾病導致的 1,700 萬人過早死亡中，38% 是由於心血管疾病。

此外，久坐的生活方式由於缺乏身體活動而導致全球血栓增加，從而增加了對抗凝劑的需求。缺乏身體活動會增加靜脈血栓栓塞症(VTE) 的風險，包括肺動脈栓塞(PE) 和深層靜脈栓塞症血栓 (DVT)。當腿部深層靜脈形成血塊時，就會發生深部靜脈血栓（DVT）；當血塊從深部靜脈流向肺部時，就會發生肺栓塞（PE）。根據美國國家醫學圖書館的數據，VTE（包括 DVT 和 PE）每年影響美國約 90 萬人。結果，數十萬人住院，約30萬人死亡。 VTE 盛行率的增加和對有效治療方案的需求不斷增加預計將推動市場發展。

此外，它還透過促進技術創新、提高抗凝血治療的有效性和安全性以及改善患者監測和結果，在振興抗凝血市場方面發揮關鍵作用。藥物發現和開發的進步導致新型抗凝血劑具有改進的特性，例如更長的半衰期、減少與其他藥物的相互作用以及降低出血風險。這些新型抗凝血劑為患者提供了更多的治療選擇和更好的結果。據美國國立衛生研究院稱，基因療法是一種治療血栓的新方法，利用基因來糾正導致血栓的潛在遺傳缺陷。儘管這種方法仍處於開發的早期階段，但它有可能成為有效治療方法血栓的方法。例如，2022年11月，FDA核准基因治療藥物Hemgenix用於治療使用預防性因子IX製劑反覆嚴重出血的B型血友病型血友病成年患者。這是一種一次性基因療法，將凝血因子 IX 的基因注射到肝臟。

抗凝血劑市場報告亮點

  • 新型口服抗凝血劑 (NOAC) 由於易於使用且減少了監測需求，有助於提高治療方案的依從性，因此在 2023 年佔據藥物類別細分市場的主導地位。
  • 肝素和低分子肝素 (LMWH) 領域預計在預測期內將以最快的複合年成長率成長。
  • 口服製劑細分市場在 2023 年佔據最大市場佔有率，預計在預測期內成長最快。
  • 久坐的生活方式、吸煙率的增加和空氣污染的增加導致心血管疾病的盛行率增加。
  • 由於心律不整監測和管理的重要性日益增加，心房顫動/心肌梗塞（心臟病發作）在 2023 年佔據了應用領域的主導地位。
  • 由於先進的醫療基礎設施、有利的法規環境以及公眾對抗凝血治療的認知不斷提高等因素，北美佔據了市場主導地位。
  • 2022年2月，FDA授予拜耳公司抗凝血劑Asundexian（BAY2433334）快速通道資格。這種口服血栓症因子是。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章抗凝血劑市場：變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 抗凝血劑市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章抗凝血藥市場：藥品分類預估及趨勢分析

  • 2023年及2030年藥品分類市場佔有率
  • 細分儀表板
  • 按藥物分類的全球抗凝血劑市場展望
  • 2018年至2030年市場規模、預測與趨勢分析

第5章抗凝血藥物市場：給藥途徑預估及趨勢分析

  • 2023 年及 2030 年給藥途徑市場佔有率
  • 細分儀表板
  • 按給藥途徑的全球抗凝血劑市場展望
  • 2018年至2030年市場規模、預測與趨勢分析

第6章抗凝血劑市場：應用估算與趨勢分析

  • 2023年及2030年應用市場佔有率
  • 細分儀表板
  • 全球抗凝血劑市場應用展望
  • 2018年至2030年市場規模、預測與趨勢分析

第7章抗凝血藥物市場：區域估算及趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概述
  • 2018-2030年市場規模及預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商形勢
    • Aspen Holdings
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • GSK plc
    • Sanofi
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • DAIICHI SANKYO COMPANY, LIMITED
    • Johnson &Johnson Services, Inc.
    • Eisai Co., Ltd.
Product Code: GVR-4-68040-191-0

Anticoagulants Market Growth & Trends:

The global anticoagulants market is anticipated to reach USD 60.4 billion by 2030 and is expected to expand at a CAGR of 8.7% during the forecast period of 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing prevalence of cardiovascular diseases (CVDs) and growing aging population. According to WHO, in 2019, CVDs caused majority of deaths worldwide, accounting for 17.9 million fatalities, which is 32% of global deaths. Among these deaths, 85% were attributed to heart attack and stroke. Moreover, of the 17 million premature deaths caused by noncommunicable diseases, 38% were due to CVDs in the same year.

Moreover, sedentary lifestyles significantly contribute to the global rise of blood clots owing to physical inactivity, fueling the demand for anticoagulants. Physical inactivity has been linked to an increased risk of venous thromboembolism (VTE), a condition that encompasses pulmonary embolism (PE) and deep vein thrombosis (DVT). The condition arises when a blood clot occurs in a deep vein in the legs, while PE occurs when a blood clot travels from a deep vein to the lungs. As per the National Library of Medicine, VTE, which includes DVT and PE, impacts around 900,000 individuals in the U.S. annually. This led to several hundred thousand hospitalizations and approximately 300,000 deaths. The increasing prevalence of VTE and the growing demand for effective treatment options is expected to boost the market.

Furthermore, technological advancements are playing a significant role in boosting the anticoagulants market by driving innovation, improving the efficacy and safety of anticoagulant treatments, and enhancing patient monitoring and outcomes. Advancements in drug discovery and development have led to the creation of new anticoagulants with improved properties, such as longer half-lives, fewer interactions with other medications, and reduced bleeding risks. These novel anticoagulants offer patients more treatment options and better outcomes. According to NIH, gene therapy is a new approach for treatment of blood clots that involves the use of genes to correct the underlying genetic defect that causes clotting. This approach is still in its early stage of development but has potential to be an effective treatment for blood clots. For instance, in November 2022, the FDA approved Hemgenix, a gene therapy to treat adults with hemophilia B who are using Factor IX prophylaxis and have a history of repeated, serious bleeding episodes. It is a one-time gene therapy that delivers a gene for clotting factor IX to the liver.

Anticoagulants Market Report Highlights:

  • Novel oral anticoagulants (NOACs) dominated the drug category segment in 2023 owing to their ease of use and reduced need for monitoring, contributing to better adherence to treatment plans
  • The Heparin and Low Molecular Weight Heparin (LMWH) segment is expected to grow at the fastest CAGR over the forecast period.
  • The oral segment held the largest market share in 2023 and is expected to witness fastest growth over the forecast period.
  • Sedentary lifestyle, increasing incidence of smoking, and rising air pollution are contributing to the growing prevalence of cardiovascular diseases
  • Atrial fibrillation/myocardial infarction (Heart attack) dominated the application segment in 2023 owing to rising importance of monitoring and managing arrhythmia
  • North America dominated the market owing to factors such as advanced healthcare infrastructure, favorable regulatory environment and rising public awareness of anticoagulant therapy
  • In February 2022, FDA granted Bayer AG's anticoagulant Asundexian (BAY2433334) Fast-Track designation. The oral factor Xla inhibitor is currently undergoing phase 2 trials for the potential prevention of secondary thrombosis in patients with non-cardioembolic ischemic stroke, atrial fibrillation, or more recently myocardial infarction.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug category
    • 1.2.2. Route of administration
    • 1.2.3. Application
  • 1.3. Regional scope
  • 1.4. Estimates and forecasts timeline
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased database
    • 1.6.2. GVR's internal database
    • 1.6.3. Secondary sources
    • 1.6.4. Primary research
    • 1.6.5. Details of primary research
      • 1.6.5.1. Data for primary interviews in North America
      • 1.6.5.2. Data for primary interviews in Europe
      • 1.6.5.3. Data for primary interviews in Asia Pacific
      • 1.6.5.4. Data for primary interviews in Latin America
      • 1.6.5.5. Data for Primary interviews in MEA
  • 1.7. Information or Data Analysis
    • 1.7.1. Data analysis models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity flow analysis (Model 1)
    • 1.9.2. Approach 1: Commodity flow approach
    • 1.9.3. Volume price analysis (Model 2)
    • 1.9.4. Approach 2: Volume price analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Primary Sources
  • 1.12. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Technology outlook
    • 2.2.2. Treatment outlook
    • 2.2.3. Application outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Anticoagulants Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of chronic diseases
      • 3.2.1.2. Technological advancements in development of anticoagulant products
      • 3.2.1.3. Growing adoption of Novel Oral Anticoagulants (NOACs)
      • 3.2.1.4. Rising geriatric population and increase prevalence of obesity
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High price associated with Novel Oral Anticoagulants (NOACs)
      • 3.2.2.2. Stringent government regulations and poor demand in underdeveloped countries
  • 3.3. Anticoagulants Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Anticoagulants Market: Drug Category Estimates & Trend Analysis

  • 4.1. Drug Category Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Anticoagulants Market by Drug Category Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Novel oral anticoagulants (NOACs)
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Eliquis
      • 4.4.1.3. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Xarelto
      • 4.4.1.5. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.6. Savaysa & Lixiana
      • 4.4.1.7. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.8. Pradaxa
      • 4.4.1.9. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Heparin and Low Molecular Weight Heparin (LMWH)
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Vitamin k Antagonist
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Direct thrombin inhibitors
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Others
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Anticoagulants Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Route of Administration Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Anticoagulants Market by Treatment Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Oral anticoagulants
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Injectable anticoagulants
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Anticoagulants Market: Application Estimates & Trend Analysis

  • 6.1. Application Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Anticoagulants Market by Application Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Atrial Fibrillation/Myocardial Infarction (Heart Attack)
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.2. Deep Vein Thrombosis (DVT)
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Pulmonary Embolism
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Others
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Anticoagulants Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Aspen Holdings
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Pfizer Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Bristol-Myers Squibb Company
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. GSK plc
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Sanofi
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Bayer AG
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Boehringer Ingelheim International GmbH
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. DAIICHI SANKYO COMPANY, LIMITED
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Johnson & Johnson Services, Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Eisai Co., Ltd.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America anticoagulants market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 4 North America anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 North America anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 7 U.S. anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 8 U.S. anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 9 Canada anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 10 Canada anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 11 Canada anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 12 Europe anticoagulants market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 14 Europe anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 15 Europe anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 16 Germany anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 17 Germany anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Germany anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 19 UK anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 20 UK anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 21 UK anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 22 France anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 23 France anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24 France anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 25 Italy anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 26 Italy anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 27 Italy anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 28 Spain anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 29 Spain anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 30 Spain anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 31 Denmark anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 32 Denmark anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 33 Denmark anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 34 Sweden anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 35 Sweden anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 36 Sweden anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 37 Norway anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 38 Norway anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 Norway anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific anticoagulants market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 44 China anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 45 China anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 46 China anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 47 Japan anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 48 Japan anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 49 Japan anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 50 India anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 51 India anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 52 India anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 53 South Korea anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 54 South Korea anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 55 South Korea anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 56 Australia anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 57 Australia anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 58 Australia anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 59 Thailand anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 60 Thailand anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 61 Thailand anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 62 Latin America anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 63 Latin America anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 64 Latin America surgical ablation market, by application, 2018 - 2030 (USD Million)
  • Table 65 Latin America laparoscopic ablation market, by application, 2018 - 2030 (USD Million)
  • Table 66 Latin America percutaneous ablation market, by application, 2018 - 2030 (USD Million)
  • Table 67 Latin America anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 68 Brazil anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 69 Brazil anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 70 Brazil surgical ablation market, by application, 2018 - 2030 (USD Million)
  • Table 71 Brazil laparoscopic ablation market, by application, 2018 - 2030 (USD Million)
  • Table 72 Brazil percutaneous ablation market, by application, 2018 - 2030 (USD Million)
  • Table 73 Brazil anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 74 Mexico anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 75 Mexico anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 76 Mexico surgical ablation market, by application, 2018 - 2030 (USD Million)
  • Table 77 Mexico laparoscopic ablation market, by application, 2018 - 2030 (USD Million)
  • Table 78 Mexico percutaneous ablation market, by application, 2018 - 2030 (USD Million)
  • Table 79 Mexico anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 80 Argentina anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 81 Argentina anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 82 Argentina surgical ablation market, by application, 2018 - 2030 (USD Million)
  • Table 83 Argentina laparoscopic ablation market, by application, 2018 - 2030 (USD Million)
  • Table 84 Argentina percutaneous ablation market, by application, 2018 - 2030 (USD Million)
  • Table 85 Argentina anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 86 MEA anticoagulants market, by region, 2018 - 2030 (USD Million)
  • Table 87 MEA anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 88 MEA anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 89 MEA anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 90 South Africa anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 91 South Africa anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 92 South Africa anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 93 Saudi Arabia anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 94 Saudi Arabia anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 95 Saudi Arabia anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 96 UAE anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 97 UAE anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 98 UAE anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 99 Kuwait anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 100 Kuwait anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 101 Kuwait anticoagulants market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Anticoagulants market: market outlook
  • Fig. 14 Anticoagulants competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Anticoagulants market driver impact
  • Fig. 20 Anticoagulants market restraint impact
  • Fig. 21 Anticoagulants market strategic initiatives analysis
  • Fig. 22 Anticoagulants market: Drug category movement analysis
  • Fig. 23 Anticoagulants market: Drug category outlook and key takeaways
  • Fig. 24 Novel oral anticoagulants (NOACs) market estimates and forecast, 2018 - 2030
  • Fig. 25 Heparin and Low Molecular Weight Heparin (LMWH) estimates and forecast, 2018 - 2030
  • Fig. 26 Vitamin k Antagonist market estimates and forecast, 2018 - 2030
  • Fig. 27 Direct thrombin inhibitors estimates and forecast, 2018 - 2030
  • Fig. 28 Others estimates and forecast, 2018 - 2030
  • Fig. 29 Anticoagulants Market: Route of administration movement Analysis
  • Fig. 30 Anticoagulants market: Route of administration outlook and key takeaways
  • Fig. 31 Oral anticoagulants market estimates and forecasts, 2018 - 2030
  • Fig. 32 Injectable anticoagulants market estimates and forecasts,2018 - 2030
  • Fig. 33 Anticoagulants market: Application movement analysis
  • Fig. 34 Anticoagulants market: Application outlook and key takeaways
  • Fig. 35 Atrial fibrillation/myocardial infarction (heart attack) market estimates and forecasts, 2018 - 2030
  • Fig. 36 Deep Vein Thrombosis (DVT) market estimates and forecasts,2018 - 2030
  • Fig. 37 Pulmonary embolism market estimates and forecasts, 2018 - 2030
  • Fig. 38 Other market estimates and forecasts,2018 - 2030
  • Fig. 39 Global anticoagulants market: Regional movement analysis
  • Fig. 40 Global anticoagulants market: Regional outlook and key takeaways
  • Fig. 41 Global anticoagulants market share and leading players
  • Fig. 42 North America market share and leading players
  • Fig. 43 Europe market share and leading players
  • Fig. 44 Asia Pacific market share and leading players
  • Fig. 45 Latin America market share and leading players
  • Fig. 46 Middle East & Africa market share and leading players
  • Fig. 47 North America: SWOT
  • Fig. 48 Europe SWOT
  • Fig. 49 Asia Pacific SWOT
  • Fig. 50 Latin America SWOT
  • Fig. 51 MEA SWOT
  • Fig. 52 North America, by country
  • Fig. 53 North America
  • Fig. 54 North America market estimates and forecasts, 2018 - 2030
  • Fig. 55 U.S. key country dynamics
  • Fig. 56 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 57 Canada key country dynamics
  • Fig. 58 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 59 Europe
  • Fig. 60 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 61 UK key country dynamics
  • Fig. 62 UK market estimates and forecasts, 2018 - 2030
  • Fig. 63 Germany key country dynamics
  • Fig. 64 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 65 France key country dynamics
  • Fig. 66 France market estimates and forecasts, 2018 - 2030
  • Fig. 67 Italy key country dynamics
  • Fig. 68 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 69 Spain key country dynamics
  • Fig. 70 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 71 Denmark key country dynamics
  • Fig. 72 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 73 Sweden key country dynamics
  • Fig. 74 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 75 Norway key country dynamics
  • Fig. 76 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 77 Asia Pacific
  • Fig. 78 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 79 China key country dynamics
  • Fig. 80 China market estimates and forecasts, 2018 - 2030
  • Fig. 81 Japan key country dynamics
  • Fig. 82 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 83 India key country dynamics
  • Fig. 84 India market estimates and forecasts, 2018 - 2030
  • Fig. 85 Thailand key country dynamics
  • Fig. 86 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 87 South Korea key country dynamics
  • Fig. 88 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 89 Australia key country dynamics
  • Fig. 90 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 91 Latin America
  • Fig. 92 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 93 Brazil key country dynamics
  • Fig. 94 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 95 Mexico key country dynamics
  • Fig. 96 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 97 Argentina key country dynamics
  • Fig. 98 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 99 Middle East and Africa
  • Fig. 100 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 101 South Africa key country dynamics
  • Fig. 102 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 103 Saudi Arabia key country dynamics
  • Fig. 104 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 105 UAE key country dynamics
  • Fig. 106 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 107 Kuwait key country dynamics
  • Fig. 108 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 109 Market share of key market players- Anticoagulants market